Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company, will present at the Viruses of Microbes 2024 conference in Cairns, Australia. The event occurs from July 15-19, 2024. Steven Branston, the Australia Site Head, will deliver a presentation titled 'Advancing Bacteriophage Therapy from Discovery to Clinical Trials' on July 18 at the Phage Therapy Session 2 – Clinical Application. The presentation will cover the progress in bacteriophage therapy, a promising approach for treating antibiotic-resistant bacterial infections.

Positive

• Armata Pharmaceuticals' participation in a significant conference enhances visibility and credibility in the biotech field.
• Presentation on advancements in bacteriophage therapy could attract investor interest and partnerships.

Negative

• No new financial data or clinical trial results were disclosed, which may lead to investor uncertainty.

LOS ANGELES, July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024, in Cairns, Australia.  

Details of the presentation are as follows:

Title:	Advancing Bacteriophage Therapy from Discovery to Clinical Trials
Session:	Phage Therapy Session 2 – Clinical Application
Presenter:	Steven Branston, Australia Site Head
Day:	Thursday, July 18
Time:	11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17)
For more information: https://www.vom2024.org/

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-presentation-at-viruses-of-microbes-2024-302191113.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

What is the topic of Armata Pharmaceuticals' presentation at Viruses of Microbes 2024?

The topic is 'Advancing Bacteriophage Therapy from Discovery to Clinical Trials.'

When is Armata Pharmaceuticals presenting at the Viruses of Microbes 2024 conference?

The presentation is on July 18, 2024, from 11:20am-11:40am AEST (9:20pm-9:40pm EDT on July 17).

What is the focus of Armata Pharmaceuticals' clinical research?

Armata Pharmaceuticals focuses on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Who will represent Armata Pharmaceuticals at the Viruses of Microbes 2024 conference?

Steven Branston, the Australia Site Head, will represent Armata Pharmaceuticals.

Where is the Viruses of Microbes 2024 conference being held?

The conference is being held in Cairns, Australia, from July 15-19, 2024.